Table 2.

Birth outcomes in the women taking leflunomide and the women in the comparison groups^*

	Leflunomide group (n = 64)	Disease-matched comparison group (n = 108)	Healthy comparison group (n = 78)
Liveborn infant	56 (87.5)	95 (88.0)†	72 (92.3)
Spontaneous abortion	5 (7.8)	8 (7.4)	3 (3.9)
Stillbirth	0	1 (0.9)	0
Blighted ovum	1 (1.6)	0	0
Elective termination	1 (1.6)	2 (1.9)	0
Lost to followup	1 (1.6)	2 (1.9)	3 (3.8)
Among live births
Male sex	24 (42.9)	51 (53.7)	37 (51.4)
Twin gestation‡	4 (7.1)	2 (2.1)	1 (1.4)
Delivery by cesarean section§	27 (48.2)	27 (28.7)	18 (25.0)
Preeclampsia	6 (10.7)	3 (3.2)	4 (5.6)
Diabetes any	3 (5.4)	2 (2.1)	4 (5.6)
Source of information on presence or absence of major malformations among live births
Dysmorphologic examination	51 (91.1)	90 (94.7)	65 (90.3)
Child’s physician	2 (3.6)	0	4 (5.6)
Maternal report	3 (5.3)	5 (5.3)	3 (4.2)

^*Values are the number (%).

^† There was 1 neonatal death, which was due to necrotizing enterocolitis.

^‡ One twin of each twin pair was randomly selected for analysis.

^§P = 0.01 for 3-group comparison, by chi-square test.